Skip to content
Clinical Trials – home
Not recruiting

Pharmacokinetics, Bioavailability and Excretion of BAY 2927088 in Healthy Male Participants for Non‑Small Cell Lung Cancer

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The investigation focuses on a medication called BAY 2927088 that is being developed for the treatment of advanced non‑small cell lung cancer that carries the genetic changes known as EGFR and HER2. The main goal of the trial is to learn how much of the drug reaches the bloodstream when taken by mouth compared with a very small dose given through an intravenous infusion, and to see how the body processes and eliminates the drug.

Healthy adult men will receive a single oral tablet of the drug and, on a separate day, a tiny trace‑labeled dose given by the infusion. Blood and urine samples will be collected over several days to measure the drug and the harmless radioactivity that marks it. The study also tracks how the drug is excreted in urine and stool to understand its overall clearance. Safety checks will be performed throughout, and any side effects will be recorded.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Baseline Assessment

    After providing informed consent, you will undergo baseline assessments that include a review of your medical history, measurement of vital signs, and collection of blood and urine samples to establish your initial health status.

  2. Step 2

    Oral Tablet Administration (Part 1)

    On the scheduled day, you will take a single 40 mg coated tablet of bay 2927088 by mouth. The tablet is swallowed with water after an overnight fast, and no other medication is taken on that day.

  3. Step 3

    Intravenous Microdose Administration (Part 1)

    On a separate study day, you will receive an intravenous infusion of a microdose of bay 2927088 (approximately 15 µg, labeled with 1 µCi of carbon‑14). The infusion is delivered through a vein over a short period, typically about 30 minutes.

  4. Step 4

    Sample Collection After Oral and Intravenous Doses (Part 1)

    Following each dose, you will remain in the clinic for several hours while blood and urine samples are taken at multiple time points. These samples allow the study team to measure how much drug enters your bloodstream, how quickly it reaches its highest level, and how it is eliminated.

  5. Step 5

    Oral Radioactive Solution Administration (Part 2)

    In the second part of the study, you will take a single 40 mg oral solution of bay 2927088 that contains a radioactive label. The solution is swallowed with water, and the radioactivity enables precise tracking of the drug’s movement and breakdown in your body.

  6. Step 6

    Sample Collection After Oral Radioactive Dose (Part 2)

    After the oral solution, you will provide blood, urine, and feces samples over several days (typically up to a week). These collections help determine the total amount of drug and its metabolites that are excreted in each route, providing information on mass balance.

  7. Step 7

    Study Completion

    When all required samples have been collected and final safety checks are performed, your participation in the study is concluded. A final visit may be scheduled to review any remaining observations.

Who can join the trial?

10 criteria

  • Be able to sign a form giving informed consent, which means you agree to take part after understanding the study.
  • Be able to understand and follow the instructions given by the study staff.
  • Be between 18 and 55 years old (or the legal adult age) at the time you sign the consent form.
  • Be in good health as judged by the doctor, based on your medical history, lab tests, a physical exam, and checks of your heart and nerves.
  • Have a body weight of at least 50 kg and a body mass index (BMI) between 18 and 30, which is a way to measure if your weight is appropriate for your height.
  • Be male.
  • If you could have children, you must agree to use effective contraception (birth control) while you are sexually active during the study and for at least 3 months after the last dose, and you must not donate sperm during that time.
  • Have a vein that can be used for blood sampling, known as venous access.
  • Be willing to have several blood draws as required by the study.
  • Agree to follow the study’s dietary and fluid requirements, which include not drinking alcohol, during the treatment period.

Who cannot join the trial?

10 criteria

  • Having serious disease of vital organs such as the liver, heart, stomach or intestines, or lung scarring (called interstitial lung disease), or having a brain condition like seizures, or having other organ problems such as diabetes.
  • Having taken part in another study that gave a certain amount of radiation (between 0.1 and 1 millisievert in the past year, 1.1‑2 mSv in the past two years, 2.1‑3 mSv in the past three years, and so on).
  • Having a disease that has not been fully cured and could change how the body absorbs, distributes, breaks down, or removes the study drug.
  • Having any important illness within the four weeks before the first dose, as judged by the doctor.
  • Having a family history or personal risk for a heart rhythm problem called Torsades de pointes (often linked to a condition called long QT syndrome) or other serious irregular heartbeats.
  • Being allergic to BAY2927088, any related compounds, or any ingredient in the tablet.
  • Having a current or past cancer.
  • Having any mental health disorder, especially mood problems, or a history of thinking about or trying suicide, which could affect the ability to give consent.
  • Having conditions that cause unusually slow emptying of urine or stool, such as severe constipation (less than one bowel movement in three days) or an enlarged prostate that blocks urine flow.
  • Having had diagnostic radiation (except dental X‑rays and regular chest or bone X‑rays) at work or in another study within the past year.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • BAY 2927088 (intravenous infusion)

    This is the same investigational drug given through a needle into a vein. It is supplied as a concentrate that is mixed with fluid and infused slowly. In the study a very small, radio‑labeled amount is injected so researchers can track exactly how the drug moves through the body and is eliminated.

  • BAY 2927088 (oral solution)

    This form of the drug is a liquid that is swallowed. It is used in the second part of the trial to see how the medication is absorbed when taken as a solution and to measure how much of the drug and its radioactive label are excreted in urine and feces.

  • BAY 2927088 (coated tablet)

    This is a solid pill with a protective coating that is taken by mouth. The tablet is used in the first part of the trial to compare how well the drug is absorbed from a typical oral dose with the absorption seen after the intravenous microdose.

What is already known about the treatment

BAY 2927088 - BAY 2927088 is given as a 40 mg oral coated tablet, a 40 mg oral solution, and a 40 mg intravenous infusion of a concentrate for solution for infusion. It is currently an investigational drug being studied in clinical trials and is not yet approved for routine medical use. The medication is being developed to treat advanced non‑small cell lung cancer that carries EGFR or HER2 mutations. It works by blocking the activity of the EGFR and HER2 proteins, which slows cancer cell growth, and it belongs to the class of tyrosine‑kinase inhibitors (targeted anticancer agents).

Investigated diseases

Advanced non‑small cell lung cancer with EGFR and/or HER2 mutations - This disease is a form of lung cancer that arises from the larger airway cells rather than from small cells. It is classified as advanced when the tumor has grown beyond the original lung site or cannot be removed completely. Mutations in the EGFR or HER2 genes cause the cancer cells to divide rapidly and resist normal growth controls. As the disease progresses, the tumor can invade surrounding lung tissue and spread to lymph nodes or distant organs. Patients may notice worsening breathing problems, cough, or other symptoms as the tumor enlarges.
Trial detailsLast updated 16 Nov 2026
Age18+ yearsPhasePhase ITrial ID2022-502771-38-00Protocol code22249Estimated enrolment8 patientsSponsorBayer AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.